staufen double-stranded RNA binding protein 1Genealiases: PPP1R150 · STAU
Q-omics provides the consensus-scored STAU1 profile across patient tissues and cancer cell-line models. STAU1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, STAU1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STAU1 protein abundance shows 24,591 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where STAU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAU1 survival associations across molecular data types. STAU1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAU1 RNA expression–survival associations across cancer types. High STAU1 expression shows unfavorable associations in MESO, LGG, BLCA and KIRP, but favorable associations in KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for STAU1 RNA expression.
This table summarizes STAU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STAU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAU1 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, COAD, LUAD and BRCA. The HNSC box plot shows higher STAU1 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with STAU1 in patient tissues and cancer cell lines. In patient samples, STAU1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, STAU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
